

“Varenzin permite un abordaje más temprano y proactivo de la anemia no regenerativa asociada a la ERC”

Paula Puchalt García - *Senior Marketing Associate*

Gonzalo Remacha Castillo - *Senior Technical Consultant*

Bibliografía:

1. Chalhoub S, *et al.* Anemia of Renal Disease: What it is, what to do and what's new. *J Feline Med Surg.* 2011 Sep;13(9):629-40.
2. New therapeutic approaches to management of anemia and iron metabolism in chronic kidney disease. <https://www.iriskidney.com/treatment-of-anemia-in-cats-with-ckd>.
3. Lorbach S. *et al.* Evaluation of health-related quality of life in cats with chronic kidney disease. *J Feline Med Surg.* 2025 Sep;27(9):1098612X251367535.
4. Boyd LM *et al.* Survival in cats with naturally occurring chronic kidney disease (2000-2002). *J Vet Intern Med.* 2008 Sep-Oct;22(5):1111-7.
5. Chakrabarti, S. *et al.* Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease. *J Vet Intern Med.* 2012 Mar-Apr;26(2):275-81.
6. The Nobel Prize in Physiology or Medicine 2019. NobelPrize.org. Nobel Prize Outreach 2026. Fri. 20 Feb 2026. <<https://www.nobelprize.org/prizes/medicine/2019/summary/>>.
7. Nupur Gupta, MD, and Jay B. Wish, MD, 2017. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. *Am J Kidney Dis.* 2017;69(6):815-826.
8. Schmidt *et al.* Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats. *Journal of Veterinary Internal Medicine*, Volume 40, Issue 1, January-February 2026, aalaf079.
9. Mangold-Gehring. S. *et al.* EXPRESS: Palatability of sunflower oil-based versus aqueous verum formulations of molidustat in healthy cats. *J Feline Med Surg.* 2026 Feb 20:1098612X261428943.